Can a new biologic calm airway inflammation in COPD?
Disease control
Not yet recruiting
This phase 2 trial is testing whether an experimental drug called PRA-216 can safely reduce airway inflammation in people with moderate to severe COPD who have a specific type of inflammation (type 2). Participants will receive either PRA-216 or a placebo, and researchers will mo…
Phase: PHASE2 • Sponsor: Prana Therapies Inc • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC